ARS Pharmaceuticals, Inc. (SPRY) Q2 FY25 Earnings Call

Q2 FY25 results, source: company transcript and SEC filings
QuarterQ2 FY25
Call date2025-08-13
Length33 minutes
EPS$-0.46
EPS consensus$-0.41
Revenue$15.7M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All SPRY earnings ยท Back to SPRY overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.